News

Leqembi approved in EU as treatment for early Alzheimer’s

Leqembi (lecanemab) has won marketing authorization in the European Union for the treatment of certain adults with early Alzheimer’s disease, making it the first therapy that targets an underlying cause of the neurodegenerative condition to be approved in the region. The treatment is indicated for adults with mild…

Leqembi IV monthly maintenance dosing approved by FDA

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi with Biogen, based on the modeling of data from the Phase…

Alzamend Neuro sets trial dosage for AL001 lithium therapy

Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials. The identified dose is unlikely to require the type of intensive drug monitoring that has been a major hurdle to the…